Prospective Cohort Study with Active Surveillance for Fever in Four Dengue Endemic Countries in Latin America

Gustavo Dayan, Jose L. Arredondo, Gabriel Carrasquilla, Carmen C. Deseda, Reynaldo Dietze, Kleber Luz, Maria Selma N. Costa, Rivaldo V. Cunha, Luis C. Rey, Javier Morales, Humberto Reynales, Maria Miranda, Betzana Zambrano, Enrique Rivas, Pedro Garbes, and Fernando Noriega

Clinical Research and Development, Sanofi Pasteur, Sao Paulo, Brazil; Instituto Nacional de Pediatría, Unidad de Apoyo a la Investigación Clínica, Mexico City, Mexico; Centro de Estudios de Investigación en Salud, Fundación Santa Fe de Bogotá, Bogotá, Colombia; Caribbean Travel Medicine Clinic, San Juan, Puerto Rico; Nucleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitória, Espírito Santo, Brazil; Hospital Infantil Varela Santiago, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil; Hospital Universitário, Universidade Federal de Goiás, Goiânia, Goiás, Brazil; Hospital Universitário, Universidade Federal de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil; Instituto de Biomedicina, Unidade de Pesquisas Clínicas, Universidade Federal do Ceará, Fortaleza, Ceará, Brazil; Clinical Research and Development Puerto Rico, Guayama, Puerto Rico; Centro de Atención e Investigación Médica, Bogotá, Colombia; Clinical Research and Development, Sanofi Pasteur, Bogotá, Colombia; Clinical Research and Development, Sanofi Pasteur, Montevideo, Uruguay; Clinical Research and Development, Sanofi Pasteur, Mexico City, Mexico; Clinical Research and Development, Sanofi Pasteur, Swiftwater, Pennsylvania

Abstract. To prepare for a Phase III dengue vaccine efficacy trial, 20 investigational sites were selected for this observational study to identify dengue infections in a closed cohort (N = 3,000 children 9–16 years of age). Of 255 acute febrile episodes experienced by 235 children, 50 (21.3%) were considered serologically probable dengue, and 18 (7.7%) were considered virologically confirmed (i.e., dengue NS1 antigen positive) dengue cases. Considering the disease-free and at-risk period from study start to onset of symptoms, the overall incidence density of acute febrile episodes was 17.7 per 100 person-years of follow-up, ranging from 15.3 in Colombia to 22.0 in Puerto Rico. This study showed that all sites were capable of capturing and following up acute febrile episodes within a specific timeframe among the established cohort and to detect dengue cases.

INTRODUCTION

Dengue is an endemic disease in the Caribbean, Central and South America, and Mexico, with an increasing incidence over the last decades. This increased number of cases has been attributed to various factors, including inefficacy of the Aedes aegypti eradication program, population growth, increased urbanization, and climatic changes. In 2013, nearly 2.3 million cases of dengue disease, including over 37,000 cases of severe dengue and more than 1,200 dengue-related deaths, were reported in Latin America. This increases burden illustrates the limited effectiveness of existing disease prevention methods, based on mosquito control and personal protection, and highlights the need for a vaccine as part of integrated programs. Several dengue vaccine candidates are in development. Sanofi Pasteur’s tetravalent dengue vaccine (CYD) contains four recombinant viruses (CYD-I–IV), each with genes encoding pre-membrane and envelope proteins of one of the dengue virus (DENV) serotypes, and non-structural proteins of the attenuated yellow fever 17D vaccine virus. This vaccine has been shown to be well tolerated and immunogenic. Efficacy of this vaccine was initially assessed in a phase IIb study in Thailand, and is being evaluated in 10 countries in Latin America and South East Asia in two phase III efficacy trials (www.clinicaltrials.gov; NCT01373281 and NCT01374516).

This work describes the results of a prospective surveillance study in sites that went on to participate in the Latin American phase III efficacy trial. The objectives of this study were to identify acute febrile episodes, describe incidence density, develop and field test operational infrastructure for the efficacy trial, and describe dengue seroprevalence.

METHODS

Study design. Between June 2010 and October 2011, a prospective surveillance study in four countries was undertaken in 20 study sites. Sites were located in Brazil (Vitoria, Natal, Goiania, Campo Grande, and Fortaleza); Colombia (Yopal, Aguazul, Acaica, Girardot, La Tebaida, Montenegro, Calarcá, and Armenia); Puerto Rico (Guayama and San Juan in Puerto Rico), and Mexico (Veracruz, Valladolid, Ciudad Mante, Temixco, Tizimin) (Table 1). These sites were selected based on a review of local epidemiological information, suggesting high endemicity in the targeted age range, on the size of this age cohort, and on their estimated capacity to participate in an efficacy trial. The study was designed to continue until approximately 1 month before the start of the phase III efficacy trial at each site, with an expected duration of ~12 months but no longer than 18 months. Therefore, the duration of participation of each subject depended on the date of enrollment and the date of onset of the phase III efficacy trial in each site.

A communication plan was developed and implemented for the duration of the study. This communication plan included a community awareness campaign, meetings with key informants, teachers, parents, healthcare workers, and community members to facilitate community involvement and support, and to provide education on dengue fever and opportunities/benefits of participating in studies and cohort recruitment.

Protocol and study documents were approved by the relevant institutional review boards and ethical committees, and the national regulatory agencies. The study was conducted in accordance with good clinical practices and national regulations. Informed assent was obtained from each participant,
Population, number of laboratory-confirmed cases, and incidence in the provinces/states during the years the study was conducted

| Site          | Province/state        | 2010 Population | 2010 No. of cases | Incidence rate/100,000 | 2011 Population | 2011 No. of cases | Incidence rate/100,000 |
|--------------|-----------------------|-----------------|------------------|------------------------|-----------------|------------------|------------------------|
| Brazil†‡      | Espírito Santo         | 1,847,561       | 6,621            | 358.36                 | 1,871,187       | 11,556           | 617.58                |
| Natal        | Rio Grande do Norte   | 3,264,647       | 1,179            | 36.11                  | 3,302,061       | 4,453            | 134.86                |
| Goiânia       | Goiás                 | 6,155,266       | 24,896           | 404.47                 | 6,250,462       | 6,685            | 106.95                |
| Campo Grande  | Mato Grosso do Sul    | 2,486,257       | 22,343           | 898.66                 | 2,520,305       | 3,081            | 122.25                |
| Fortaleza     | Ceará                 | 8,569,783       | 13,817           | 161.23                 | 8,642,630       | 56,714           | 656.21                |
| Colombia§     | Casanare              | 325,621         | 2,190            | 672.56                 | 331,734         | 401              | 120.88                |
| Yopal        | Casanare              | 325,621         | 2,190            | 672.56                 | 331,734         | 401              | 120.88                |
| Acacias      | Meta                  | 870,921         | 5,600            | 643.00                 | 888,802         | 1,610           | 181.14                |
| Girardot     | Cundinamarca          | 2,477,036       | 4,251            | 171.62                 | 2,517,215       | 465             | 18.47                 |
| La Tebaida   | Quindío               | 549,662         | 9,713            | 1,767.09               | 552,755         | 224             | 40.52                 |
| Montenegro   | Quindío               | 549,662         | 9,713            | 1,767.09               | 552,755         | 224             | 40.52                 |
| Calarca      | Quindío               | 549,662         | 9,713            | 1,767.09               | 552,755         | 224             | 40.52                 |
| Armenia      | Quindío               | 549,662         | 9,713            | 1,767.09               | 552,755         | 224             | 40.52                 |
| Mexico¶      | Morelos               | 1,803,340       | 1,508            | 83.62                  | 1,827,187       | 785             | 42.96                 |
| Temixco      | Veracruz              | 7,712,247       | 1,214            | 15.74                  | 7,791,801       | 1,886           | 24.20                 |
| El Mante     | Tamaulipas            | 3,334,664       | 579              | 17.36                  | 3,376,515       | 99              | 2.93                  |
| Tizimin      | Yucatán               | 1,980,690       | 2,525            | 127.48                 | 2,009,160       | 6,197           | 308.44                |
| Valladolid   | Yucatán               | 1,980,690       | 2,525            | 127.48                 | 2,009,160       | 6,197           | 308.44                |
| Puerto Rico * †† | Puerto Rico         | 3,721,208       | 9,883            | 265.59                 | 3,686,580       | 1,458           | 39.55                 |
| Guayama      | Puerto Rico           | 3,721,208       | 9,883            | 265.59                 | 3,686,580       | 1,458           | 39.55                 |

*Projeção da população do Brasil por sexo e idade para o período 2000-2060. http://www.ibge.gov.br/home/estatistica/populacao/projeccas_da_populacao2013/default_tab.shtml.
†DATASUS Tecnologia informacão a serviço do SUS. http://tabnet.datasus.gov.br/cgi/tabwin.exe/sub/cnv/munuf.def.
‡DANE/Columbia. Available at: http://www.dane.gov.co/index.php/poblacion-y-demografia/proyecciones-de-poblacion [Update: February 2014].
§National Institutes of Health/SIVIGILA/Colombia: http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/sivigila/Paginas/sivigila.aspx [Update: February 2014].
¶CONAPO, Projections Census 2010: Mexican Population Projections 2010–2050: http://www.conapo.gob.mx/es/CONAPO/Proyecciones_de_la_Poblacion_2010-2050.
††DENG Surveillance Weekly Report, CDC Dengue Branch and Puerto Rico Department of Health: http://www.salud.gov.pr/dengue/Pages/estadisticasmasrecientes.aspx.

and informed consent was obtained from their parents or legal representative.

Surveillance system – case classification. The surveillance system was designed to detect all acute febrile episodes of at least 2 consecutive days among cohort subjects. All acute febrile episodes identified in the cohort (defined as 2 or more consecutive days of fever of ≥ 38°C) were considered as suspected symptomatic dengue cases.

Participants and parents were instructed to visit the study site or a dedicated healthcare facility in the event of an acute febrile episode and inform the investigator within 24 hours of fever onset, and were contacted weekly by telephone to ensure that this instruction was followed. Weekly telephone calls also served to identify if unreported febrile episodes had occurred since the last contact and to arrange medical visits as appropriate.

In the event of an acute febrile episode, an acute blood specimen was collected and an additional visit was scheduled to collect a convalescent specimen 7–14 days after the initial visit. The non-structural protein 1 (NS1) enzyme-linked immunosorbent assay (ELISA) antigen was performed on acute blood specimens and immunoglobulin M (IgM)/immunoglobulin G (IgG) ELISA were performed on both acute and convalescent specimens.

Suspected dengue cases with a positive IgM ELISA result or a 4-fold IgG increase were classified as probable dengue, referred to below as serologically probable. Cases with a positive NS1 ELISA antigen were classified as virologically confirmed dengue.

Dengue seroprevalence. A blood specimen to assess IgG ELISA was obtained at recruitment and at the end of the study to determine dengue seroprevalence.

Laboratory testing. Dengue NS1 Ag ELISA. The PlateliaTM Dengue NS1 Ag kit (Bio-Rad, Hercules, CA) was provided to each site. The assay was run according to manufacturer’s instructions. A sample ratio was determined for each sample by dividing the average optical density (OD) of the test sample by the average OD of the cutoff control (tested in quadruplicate). Sample ratios of c < 0.5, 0.5–c < 1.0, and ≥ 1 were indicative of negative, equivocal, and positive results, respectively.

Dengue IgM/IgG ELISA. The EL1500M Dengue IgM ELISA and EL1500G Dengue IgG ELISA kits (Focus Diagnostics, Cypress, CA) were run according to the manufacturer’s instructions. The OD of absorbance for test samples at wavelength 450 nm was divided by the cutoff value for the kit to generate an index value. Positive results were indicated by an index value > 1.0, negative results by an index value < 1.0.

Statistical methods. We aimed to recruit 150 subjects per site for a total cohort of 3,000, which was not hypothesis-driven. This sample size was based on the estimated proportion of febrile episodes in the region of 24% and addressing operational aspects to descriptively address the objectives of interest.

Assuming a proportion of febrile episodes of 24% and a sample size of 150 subjects, the probability of observing at least 32 fever events was 0.8 (binomial distribution). Analyses were descriptive with no hypothesis testing. For the main parameters, 95% confidence intervals (CIs) of point estimates were calculated using normal approximation for quantitative data and exact binomial distribution (Clopper-Pearson method) for proportions.21 For the incidence
density rates, 95% CI were calculated using the Rothman–Greenland method. 22

RESULTS

A total of 3,000 children 9–16 years of age (mean: 12.4, SD: 2.0), were enrolled (150 per site), of whom 2,954 (98.5%) completed the study. The study duration for all sites combined was 504 days and mean duration of follow-up of the subjects was 177.6 days.

Of 255 acute febrile episodes, experienced by 235 children (7.8% of participants), 50 displayed a 4-fold increase in IgG titer between acute and convalescent samples, or were positive for anti-dengue IgM and were therefore considered as serologically probable dengue cases, and 18 were positive for dengue NS1 antigen and were considered as virologically confirmed dengue cases (Table 2). That is, 50 of 235 (21.3%) children with acute febrile episodes had serologically probable dengue and 18 (7.7%) had virologically confirmed dengue. Considering only the first case for each participant, and the disease-free, at-risk period from study start to onset of symptoms, the overall incidence density of acute febrile episodes was 17.7 per 100 person-years of follow-up. This varied within the range 15.3 in Colombia to 22.0 in Puerto Rico. The incidence density of virologically confirmed dengue was 1.3 per 100 person-years; that of serologically probable dengue was 3.6 per 100 person-year, and that of serologically probable or virologically confirmed dengue was 4.1 per 100 person-years (Table 2).

Of the 50 serologically probable dengue cases, 11 (22%) were virologically confirmed. Of the 18 virologically confirmed cases, 11 (61.1%) were also serologically probable dengue cases (Table 3). Hence, the predictive negative value of the serological diagnosis was 96.2% and the specificity was 82%.

Most cases (88.9%) presented for an acute visit within 5 days after fever onset, ranging from 68.6 in Puerto Rico to 98% in Colombia (Figure 1). A similar percentage of subjects had an acute blood specimen drawn within the same interval. Most subjects (90.2%) had a convalescent blood specimen taken 7–14 days after the onset of fever, ranging from 71.4% in Brazil to 100% in Colombia.

The seroprevalence of anti-dengue serum IgG antibodies in the study population was determined at study enrollment and termination. Overall, 70.4% of the study population was positive for dengue at enrollment, ranging from 48.9% in Puerto Rico to 92.5% in Colombia, where almost a half of our study population was enrolled (Table 4). Overall, results at the end of the study were comparable with results at enrollment. Of 44 participants identified as seronegative at baseline and seroconverting during the study, our surveillance system captured 10 (~23%) who presented with fever. Of these 10, 9 subjects had probable dengue (only serological markers) and 7 subjects had virologically confirmed dengue.

DISCUSSION

This study was a unique opportunity to train the investigational teams in the field and prepare the local healthcare infrastructure for a phase III dengue vaccine efficacy study in the 9–16 years age group. The teams at all sites showed their ability to actively capture and follow-up acute febrile episodes within the timeframe specified in the protocol to confirm symptomatic dengue cases, which confirmed the feasibility of implementing an active surveillance system to detect and diagnose symptomatic dengue cases in multiple countries in Latin America.

Less than 10% of the detected febrile episodes were virologically confirmed as dengue, illustrating the importance of laboratory confirmation. Serological diagnosis of dengue (IgM/IgG) suggested that 50 cases were probable dengue, but less than one-quarter of these cases were also NS1 antigen positive. This low proportion indicates that many of the positive results from the serological testing could be false positives. Indeed antibodies elicited by other flaviviruses such as yellow fever or Japanese encephalitis, or previous dengue infections can cross-react with the dengue virus leading to false positive reactions. 23–26 Although samples were not tested for other flaviviruses, yellow fever vaccination is included in the national immunization calendars of Brazil and Colombia, and yellow fever is endemic in certain regions in these countries. Nevertheless, serological tests are broadly used and do have value in the diagnosis of dengue. Their strength is their negative predictive value, which gives a high confidence that negative results correctly identifies patients without the disease; i.e., to rule out dengue. In this study the

Table 2

| Countries | N | Acute febrile episode | Serologically probable dengue | Virologically confirmed dengue | Acute febrile episodes | Serologically probable dengue | Virologically confirmed dengue | Either Serologically probable or virologically confirmed | Both Serologically probable and virologically confirmed |
|-----------|---|-----------------------|-----------------------------|-------------------------------|------------------------|-----------------------------|-----------------------------|--------------------------------------------------------|--------------------------------------------------------|
| All       | 3000 | 235† | 50 | 18 | 17.7 (15.6; 20.1) | 3.6 (2.7; 4.8) | 1.3 (0.8; 2.1) | 4.1 (3.2; 5.4) | 0.8 (0.4; 1.4) |
| Brazil    | 750  | 42   | 15 | 5  | 20.5 (15.2; 27.8) | 7.2 (4.3; 11.9) | 2.4 (1.0; 5.7) | 7.7 (4.7; 12.5) | 1.9 (0.7; 5.1) |
| Colombia  | 1200 | 98   | 8  | 6  | 15.3 (12.5; 18.6) | 1.2 (0.6; 2.4) | 0.9 (0.4; 2.0) | 1.9 (1.1; 3.4) | 0.4 (0.1; 2.8) |
| Mexico    | 750  | 44   | 8  | 1  | 17.8 (13.2; 23.9) | 3.1 (1.6; 6.3) | 0.4 (0.1; 2.8) | 3.1 (1.6; 6.3) | 0.4 (0.1; 2.8) |
| Puerto Rico | 300 | 51   | 19 | 6  | 22.0 (16.7; 29.0) | 7.7 (4.9; 12.0) | 2.3 (1.0; 5.2) | 8.1 (5.2; 12.5) | 1.0 (0.8; 4.7) |

*Definitive as the number of new cases arising from defined population in specified time period divided by the total at risk person-time of observation.
†20 participants experienced two episodes, i.e., there was a total of 255 episodes.

Table 3

| Subjects with at least one | Incidence density (95% confidence interval) per 100 person-years |
|---------------------------|---------------------------------------------------------------|
| Countries                 | N | Acute febrile episode | Serologically probable dengue | Virologically confirmed dengue | Acute febrile episodes | Serologically probable dengue | Virologically confirmed dengue | Either Serologically probable or virologically confirmed | Both Serologically probable and virologically confirmed |
| All                       | 3000 | 235† | 50 | 18 | 17.7 (15.6; 20.1) | 3.6 (2.7; 4.8) | 1.3 (0.8; 2.1) | 4.1 (3.2; 5.4) | 0.8 (0.4; 1.4) |
| Brazil                    | 750  | 42   | 15 | 5  | 20.5 (15.2; 27.8) | 7.2 (4.3; 11.9) | 2.4 (1.0; 5.7) | 7.7 (4.7; 12.5) | 1.9 (0.7; 5.1) |
| Colombia                  | 1200 | 98   | 8  | 6  | 15.3 (12.5; 18.6) | 1.2 (0.6; 2.4) | 0.9 (0.4; 2.0) | 1.9 (1.1; 3.4) | 0.4 (0.1; 2.8) |
| Mexico                    | 750  | 44   | 8  | 1  | 17.8 (13.2; 23.9) | 3.1 (1.6; 6.3) | 0.4 (0.1; 2.8) | 3.1 (1.6; 6.3) | 0.4 (0.1; 2.8) |
| Puerto Rico               | 300  | 51   | 19 | 6  | 22.0 (16.7; 29.0) | 7.7 (4.9; 12.0) | 2.3 (1.0; 5.2) | 8.1 (5.2; 12.5) | 1.0 (0.8; 4.7) |

*PPV = predictive positive value.
†PVN = predictive negative value.
Platelia NS1 ELISA assay was used as a cost-efficient option to virologically diagnose dengue. Although this test is very specific, it has shown to be less sensitive for specimens collected after the first days of illness and for secondary infections.\textsuperscript{27–29} In one dengue outbreak in Santos, Brazil, where most cases were secondary infection by dengue 2 virus, NS1 was reactive in 37.7% of RNA\textsuperscript{+} specimens evidenced by real-time polymerase chain reaction (RT-PCR).\textsuperscript{30} Therefore, virological confirmation should ideally be sought using additional assays to detect the dengue virus, such as RT-PCR. This test, in addition to NS1, should be part of the testing algorithm for virological confirmation in vaccine efficacy trials.

Routine passive surveillance systems do not normally have the capacity to detect all dengue cases.\textsuperscript{31} Therefore, to calculate a more accurate estimate of real incidence, the cases reported through routine surveillance systems need to be multiplied by correction or expansion factors, which represent the degree of underreporting.\textsuperscript{32} Different underreporting rates have been reported in Latin America.\textsuperscript{33–37} Additionally, higher reporting rates have been documented with the use of an enhanced surveillance system.\textsuperscript{38} The incidence rates observed in our study confirm the high incidence of dengue in children and adolescents from 9 to 16 years of age in these sites.

Our study has several limitations. The timing of participation was not the same for all subjects in the study. Consequently, exposure to dengue may have differed depending on the season of participation in the study. For example, in Colombia in 2010, the dengue incidence peaked in the first half

![Figure 1](image-url)  
**Figure 1.** Percentage of subjects with an acute febrile episode who presented for an acute visit (A), with acute blood specimens within 5 days of fever onset (B), and convalescent specimens within 7–14 days of fever onset (C).

### Table 4

| Study countries/sites | Positive at baseline | Positive at the end of the study |
|-----------------------|----------------------|----------------------------------|
|                       | n/N                  | %                                | 95% CI              | n/N      | %                  | 95% CI              |
| All countries         | 1821/2588            | 70.4                             | (68.6; 72.1)        | 1839/2595| 70.9               | (69.1; 72.6)        |
| Brazil                | 249/449              | 55.5                             | (50.7; 60.1)        | 263/452  | 58.2               | (53.5; 62.8)        |
| Colombia              | 1086/1174            | 92.5                             | (90.8; 93.9)        | 1079/1176| 91.8               | (90.0; 93.3)        |
| Mexico                | 353/693              | 59.9                             | (47.1; 54.7)        | 352/695  | 50.6               | (46.9; 54.4)        |
| Puerto Rico           | 133/272              | 48.9                             | (42.8; 55.0)        | 145/272  | 53.3               | (47.2; 59.4)        |

*\textit{n} = number of subjects that met the specified criteria (IgG positive); \textit{N} = number of subjects with a valid dengue IgG ELISA result; CI = confidence interval.
of the year, with an important drop of cases reported in the second half. Study participants from Colombia were included mostly in September 2010 and followed up until May 2011, considered as a year with low incidence of dengue.\(^{39}\) Differences in incidence should therefore be interpreted with caution, and although our results suggest that incidence may be higher than those reported through routine surveillance systems, accurate comparisons cannot be made because passive surveillance data for the same age group and catchment areas were not collected. This study has shown the capacity of the surveillance system to rapidly detect and obtain acute specimens on the majority of febrile cases, however information on the source of case detection (e.g., self-reported or weekly phone contact) was not systematically collected and could not be analyzed. Another limitation was the lack of testing for other flaviviruses that may have been helpful in the case of samples that were showed a serological response to dengue, but were negative in the virological assay. Finally, it was not meaningful to calculate incidence by site because of the small number of dengue cases by site.

The successful implementation of an active surveillance system and the virologically confirmed dengue activity in all countries in our study confirmed the suitability of these investigational sites to participate in the phase III efficacy study that enrolled more than 20,000 participants from 2011, and is scheduled to conclude in 2014.

Received November 15, 2013. Accepted for publication October 11, 2014.

Published online May 26, 2015.

Acknowledgments: We thank Grenville Marsh at Sanofi Pasteur for providing editorial assistance.

Financial support: This study was sponsored by Sanofi-Pasteur.

Authors’ addresses: Gustavo Dayan and Fernando Noriega, Clinical Research and Development, Sanofi Pasteur, Swiftwater, PA, E-mails: gustavo.dayan@sanofipasteur.com and fernando.noriega@sanofipasteur.com. Jose L. Arredondo, Instituto Nacional de Pediatría, Unidad de Apoyo a la Investigación Clínica, Insurgentes Sur Cuicuilco, Mexico City, México, E-mail: arredondo.joseelis@gmail.com. Gabriel Carrasquilla, Centro de Estudios de Investigación en Salud (CEIS), Fundación Santa Fe de Bogotá, Bogotá, Colombia, E-mail: Gabriel.Carrasquilla@fsfb.org.co. Carmem C. Deseda, Canibael Travel Medicine Clinic, San Juan, PR, E-mail: desedamd@hotmail.com. Reynaldo Dietz-Tejedor, Universidad Federal do Espírito Santo, Núcleo de Doenças Infecciosas/CBM/UFES, Maruípe, Vitória, Espírito Santo, Brazil, E-mail: rdietzte@ndi.ufes.br. Cleber Luiz, Hospital Infantil Varela Santiago, Universidad Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil, E-mail: klebergluz@gmail.com. María Selma N. Costa, Universidad Federal de Goiás Hospital das Clínicas, Primeira Avenida s/número, Universitário, Goiânia, Goiás, Brazil, E-mail: m.selma@uol.com.br. Rivaldo V. Cunha, Universidade Federal de Mato Grosso do Sul, Facultade de Medicina/UFMS, Departamento de Clínica Médica, Universitário, Campo Grande, Mato Grosso do Sul, Brazil, E-mail: rivaldo_.venancio@uol.com.br. Luís C. Rey, Universidade Federal do Ceará - Instituto de Biomedicina, Rua Coronel Nunes de Melo 1315, Unidade de Pesquisas Clínicas – IBIMED, Rodelfo Teófilo, Fortaleza, Ceará, Brazil, E-mail: reyulse@gmail.com. Javier Morales, Clinical Research Puerto Rico, San Juan, PR, E-mail: crp@clinicalresearchpr.com. Humberto Rey内, Centro de Atención en Investigación Médica (CAIMED), Bogotá, Colombia, E-mail: humberto.reynes@caimed .com. Maria Miranda, City Business Piso 9, Bogotá, Colombia, E-mail: maria.miranda@sanofipasteur.com. Betzana Zambrano, Edif Corporate El Plata – Francisco García Cortinas 2357, Montevideo, Uruguay, E-mail: betzana.zambrano@sanofipasteur.com. Enrique Rivas, Mexico City, Mexico, E-mail: enrique.rivas@sanofipasteur .com. Pedro Garbes, Clinical Research and Development, Miami Building, Jardim Morumbi, São Paulo, Brazil, E-mail: pedro.garbes@ sanofipasteur.com.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. San Martín JL, Brathwaite O, Zambrano B, Solórzano JO, Bouckenoogohe A, Dayan GH, Guzmán MG, 2010. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 82: 128–135.

2. Padilla JC, Rojas DP, Sánchez-Gomez R, 2012. Dengue en Colombia: Epidemiología de la Reemergencia a la Hiperendemia. Bogotá, Colombia: Guías de Impresión LTDA.

3. Sequeira M, Espinoza H, Amador JJ, Domingo G, Quintanilla M, de los Santos T, 2011. Dengue in Nicaragua. Available at: http://www.path.org/publications/files/TS_nicaragua_dengue_rpt .pdf. Accessed October 11, 2013.

4. Teixeira MG, Costa NM, Coelho G, Barreto ML, 2008. Recent shift in age pattern of dengue hemorrhagic fever, Brazil. Emerg Infect Dis 14: 1663.

5. Shepard DS, Covodeville L, Halasa YA, Zambrano B, Dayan GH, 2011. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg 84: 200–207.

6. Hurtadá-Díaz M, Riosas-Rodríguez H, Rothenberg SJ, González-Dantés H, Cifuentes E, 2007. Short communication: impact of climate variability on the incidence of dengue in Mexico. Trop Med Int Health 12: 1327–1337.

7. Barclay E, 2008. Is climate change affecting dengue in the Americas? Lancet 373: 973–974.

8. Pan American Health Organization (PAHO), Dengue. 2013. Available at: http://new.paho.org/hq/index.php?option=com_content&task=view&id=264&Itemid=363&lang=es. Accessed March 20, 2014.

9. Coller BA, Clemens DE, 2011. Dengue vaccines: progress and challenges. Curr Opin Immunol 23: 391–398.

10. Guirakcho F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Rattercek M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP, 2000. Recombinant chimeric yellow fever-dengue type virus is immunogenic and protective in nonhuman primates. J Virol 74: 5477–5485.

11. Guirakcho F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Rattercek M, Monath TP, 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever–dengue virus tetravalent vaccine. J Virol 75: 7290–7304.

12. Capeding RZ, Luna IA, Bomasang E, Lapisan S, Lang J, Forrat R, Wartel A, Crevat D, 2011. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 29: 3863–3872.

13. Guirakcho F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, Bedford P, Lang J, Quentín-Millet MJ, Monath TP, 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax®-DENV2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2: 60–67.

14. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J, 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 201: 370–377.

15. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J, 2011. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 85: 724–731.

16. Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, Saville M, Crevat D, 2012. Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds.
previously vaccinated against yellow fever; randomized, controlled, phase II study in Piura, Peru. Vaccine 30: 5935–5941.

17. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH, 2011. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase I trial of safety and immunogenicity. Pediatr Infect Dis J 30: e9–e17.

18. Sin LY, Wilder-Smith A, Archuleta S, Shek L, Chong CY, Nam LH, Yong LC, Oh ML, Bouckenooghe A, Crevat D, Wartel A, 2012. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 8: 1259–1271.

19. Villar LA, Rivera-Medina DM, Arredondo-Garcia JL, Boaz M, Starr-Spires L, Thakur M, Zambrano B, Miranda MC, Rivas E, Dayan GH, 2013. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16-year-olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 32: 1102–1109.

20. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwarirayavej V, Dulyachai W, Pongsa K, Wartel TA, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J, 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomized, controlled phase 2b trial. Lancet 380: 1559–1567.

21. Clopper C, Pearson ES, 1934. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26: 404–413.

22. Rothman KJ, Greenland S, 1998. Modern Epidemiology. Second edition. New York, NY: Lippincott-Raven.

23. World Health Organization, 1997. Dengue Hemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Second edition. Geneva: World Health Organization.

24. Blacksell SD, Newton PN, Bell D, Kelley J, Mammen MP, Vaughn DW, Wuthichakan V, Sungkakum A, Nisalak A, Day NP, 2006. The comparative accuracy of 8 rapid immunochromatographic assays for the diagnostic of acute dengue virus infection. Clin Infect Dis 42: 1127–1134.

25. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, Pelegrino JL, Vazquez S, Artsob H, Drebot M, Gubler DJ, Halstead SB, Guzman MG, Margolis HS, Nathanson CM, Rizzo L, NR, Bessoff KE, Kliks S, Peeling RW, 2009. Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis 15: 436–440.

26. Vaughn DW, Nisalak A, Solomon T, Kalayanarooj S, Dung NM, Kneen R, Cuzzubbo A, Devina PL, 1999. Rapid serologic diagnosis of dengue virus infection using a commercial capture ELISA that distinguishes primary and secondary infections. Am J Trop Med Hyg 60: 693–698.

27. Guzman MG, Jaenisch T, Gaczkowski R, Hang VT, Sekaran SD, Kroeger A, Vazques S, Ruiz D, Martinez E, Mercado JC, Balmaseda A, Harris E, Dimano E, Leano PSA, Yoksan S, Villegas E, Benduzu H, Villalobos I, Farrar J, Simmons CP, 2010. Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis 4: e811.

28. Hang VT, Nguyen NM, Trung DT, Tricou V, Yoksan S, Dung NM, Ngoc TV, Hien TT, Farrar J, Wills B, Simmons CP, 2009. Diagnostic accuracy of NS1ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. PLoS Negl Trop Dis 3: e360.

29. Lapphra K, Sangharaswihai A, Chokephaibulkit K, Tiengrim S, Kuhnt CL, Harris E, Dimano E, Leano PSA, Yoksan ELISA that distinguishes primary and secondary infections. Emerg Infect Dis 15: 436–440.

30. Felix AC, Romano CM, Centrone Cde C, Rodrigues CL, Villas-Boas L, Araujo ES, de Matos AM, Carvalho KI, Turchi Martelli CM, Kallas EG, Pannuti CS, Levi JE, 2012. Low sensitivity of NS1 protein tests evidenced during a dengue type 2 virus outbreak in Santos, Brazil, in 2010. Clin Vaccine Immunol 19: 1972–1976.

31. Gubler D, 2002. How effectively is epidemiological surveillance used for dengue programme planning and epidemic response? Dengue Bull 26: 96–106.

32. Suaya JA, Shepard DS, Farrar J, 2010. Disease burden of dengue fever and dengue hemorrhagic fever. Preedy VR, Watson RR, eds. Handbook of Disease Burdens and Quality of Life Measures. New York, NY: Springer, 1263–1279.

33. Luz PM, Grinsztejn B, Galvani AP, 2009. Disability adjusted life years lost to dengue in Brazil. Trop Med Int Health 14: 237–246.

34. Armien B, Suaya JA, Quiroz E, Sah BK, Bayard V, Marchena L, Campos C, Shepard DS, 2008. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am J Trop Med Hyg 79: 364–371.

35. Meltzer MI, Rigau-Perez JG, Clark GG, Reiter P, Gubler DJ, 1998. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984–1994. Am J Trop Med Hyg 59: 265–271.

36. Camacho T, de la Hoz F, Cardenas V, Sanchez C, de Calderon L, Perez L, Bermudez A, 2004. Incomplete surveillance of a dengue-2 epidemic in Ibague, Colombia, 1995–1997. Biomedica 24: 174–182.

37. Strandish K, Kuan G, Aviles W, Balmaseda A, Harris E, 2010. High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. PLoS Negl Trop Dis 4: e633.

38. Ramos MM, Arguello DF, Luxemburger C, Quinones L, Muñoz JL, Beatty M, Lang J, Tomasetik M, 2008. Epidemiological and clinical observations on patients with dengue in Puerto Rico: results from the first year of enhanced surveillance—June 2005–May 2006. Am J Trop Med Hyg 79: 123–127.

39. Restrepo AC, Baker P, Clements AC, 2014. National spatial and temporal patterns of notified dengue cases, Colombia 2007–2010. Trop Med Int Health 19: 863–871.